![]() | |
Clinical data | |
---|---|
Trade names | Xofluza |
Other names | BXM (S-033188), BXA (S-033447) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618062 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H23F2N3O7S |
Molar mass | 571.55 g·mol−1 |
3D model (JSmol) | |
| |
|
Baloxavir marboxil, sold under the brand name Xofluza, is an antiviral medication for treatment of influenza A and influenza B.[4] It was approved for medical use both in Japan and in the United States in 2018,[7][8][9] and is taken as a single dose by mouth.[4] It may reduce the duration of flu symptoms by about a day, but is prone to selection of resistant mutants that render it ineffectual.[10][unreliable medical source?]
Baloxavir marboxil was developed as a prodrug strategy, with its metabolism releasing the active agent, baloxavir acid (BXA). Baloxavir acid then functions as enzyme inhibitor, targeting the influenza virus' cap-dependent endonuclease activity, used in "cap snatching" by the virus' polymerase complex, a process essential to its life-cycle.[11]
The most common side effects of baloxavir marboxil include diarrhea, bronchitis, nausea, sinusitis, and headache.[12]
The US Food and Drug Administration (FDA) considers baloxavir marboxil to be a first-in-class medication.[13]
Xofluza FDA label
was invoked but never defined (see the help page).Xofluza EPAR
was invoked but never defined (see the help page).FDA approval 2018
was invoked but never defined (see the help page).FDA approval 2019
was invoked but never defined (see the help page).FDA PR 20201123
was invoked but never defined (see the help page).